CRP and acute coronary syndrome: The Atorvastatin for Reduction of Myocardial Damage during Angioplasty (ARMYDA) (6), ARMYDA-acute coronary syndromes (8), ARMYDA-RECAPTURE (10) and Novel Approaches for Preventing or Limiting Events II (9) studies demonstrated that pretreatment with atorvastatin significantly reduced procedural CRP levels of patients with SAP, UAP and NSTEMI in elective coronary intervention.